Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | CHIEF MEDICAL OFFICER | August 14, 2024 | August 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date August 14, 2024 · Filed August 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 325,711 |
Reported balance
After 2024-08-14 transaction · row 1
1 source rowRow 1 · 2024-08-14 · Sale · Disposed 1,365 · Balance 325,711 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2021 Filed Apr 13, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 284 | $63.51 | $18,036.70 |
DisclosureSEC source: 0000899243-21-015610 · doc4.xml · nonDerivative · entry 5 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,750 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.05 to $63.77, inclusive. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 259 | $61.59 | $15,953.05 |
DisclosureSEC source: 0000899243-21-015610 · doc4.xml · nonDerivative · entry 4 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,034 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.07 to $61.965, inclusive. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,941 | $60.29 | $177,299.36 |
DisclosureSEC source: 0000899243-21-015610 · doc4.xml · nonDerivative · entry 3 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,293 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.98, inclusive. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,000 | $59.15 | $59,148.00 |
DisclosureSEC source: 0000899243-21-015610 · doc4.xml · nonDerivative · entry 2 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,234 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.93 to $59.38, inclusive. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,903 | $58.06 | $168,540.63 |
DisclosureSEC source: 0000899243-21-015610 · doc4.xml · nonDerivative · entry 1 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,234 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.74 to $58.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:39 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 100 | $76.69 | $7,669.00 |
DisclosureSEC source: 0000899243-21-011448 · doc4.xml · nonDerivative · entry 4 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,137 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:39 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,146 | $75.20 | $86,176.68 |
DisclosureSEC source: 0000899243-21-011448 · doc4.xml · nonDerivative · entry 3 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,237 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.90 to $75.86, inclusive. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:39 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 4,844 | $74.35 | $360,150.92 |
DisclosureSEC source: 0000899243-21-011448 · doc4.xml · nonDerivative · entry 2 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,383 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.88 to $74.82, inclusive. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:39 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,297 | $73.38 | $95,176.58 |
DisclosureSEC source: 0000899243-21-011448 · doc4.xml · nonDerivative · entry 1 Randolph Sophia · CIK 0001817127 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,227 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.76 to $73.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 19:04 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 89,657 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019577 · doc4.xml · derivative · entry 1 Randolph Sophia · CIK 0001817127 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,657 Underlying: Common Stock · 89,657 shares Expires 2030-07-16 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 16, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.